The increased risk of post-treatment contrast-enhancing brain lesion in IMPT of glioma, and the mitigation thereof in treatment planning

Abstract

Proton radiotherapy has a dosimetric advantage over photon therapy to spare healthy tissue closely positioned to the tumor mainly due to the absent exit dose. In The Netherlands, the Proton therapy centers currently take a relative biological effectiveness (RBE) of 1.1 compared to photons to deliver an iso-effective treatment. However, initial clinical evidence indicates a variable proton RBE in brain patients with the linear energy transfer (LET) as an important physical parameter. The LET significantly increases at the end of the radiation field, and contributes to an increased probability to develop brain lesions. With the introduction of radiation response models, the first goal of this thesis is to evaluate the impact of the RBE/LET effect in intensity-modulated proton therapy (IMPT) plans. Furthermore, the main goal is to reduce the RBE/LET effect in treatment planning.

We incorporated the probability of lesions origin (POLO) model published in literature to determine the RBE model-based normal tissue complication probability (NTCP) for three glioma patients treated with IMPT at HollandPTC, The Netherlands. The dose and LET distributions were computed using a Monte Carlo system. For the investigation of the RBE/LET effect in treatment planning, we modified several beam settings of the clinical IMPT plan, including the beam angle, beam energy, and robustness. Furthermore, we combined treatment modalities to reduce the NTCP.

We compared the results of the clinically used IMPT plan with the results obtained by the modified IMPT plans. The local redistribution of LETd leads to a decrease in NTCP up to the point when the LETd becomes uniform. The robustness did not reveal deviations in terms of the NTCP. By choosing appropriate beam angles that result in a smeared out
LETd distribution, the NTCP does not improve for small deep located tumors, improves relatively modest by 11.6% for elongated tumors, and significantly improves by 37.0% for large, superficially located tumors. The inclusion of partial transmission beams lowers the NTCP by 30-50% relative to the clinical IMPT plan while limiting the relative increase in mean brain dose by 5-16%. When comparing the IMPT plan with the photon plan used for plan comparison, the VMAT plan always results in the lowest NTCP and provides a relative improvement in NTCP by 60-75%. Meanwhile, the mean brain dose significantly increases by 50-80% compared to the clinical IMPT plan. Intermediate NTCP-Dmean(brain minus CTV) values are achieved when combining protons with the photons or by including proton transmission beams.

In general, we can conclude that the inclusion of partial proton transmission beams is more promising than choosing appropriate beam angles to lower the RBE/LETd effect. However, further optimization of transmission beams is required. Moreover, an improvement in NTCP is always at the cost of the mean dose to healthy tissue. On top, our results support further investigation to combine different modalities, like protons and photon fractionation.